Oxulumis™ is a semi-automated ocular administration device engineered for minimally invasive delivery of retinal therapeutics into the suprachoroidal space of the eye.

The ergonomic design of Oxulumis™ allows for single-handed, in-office administration by a trained physician. Administration is similar to an intravitreal injection, is performed in approximately 30 seconds and requires no special equipment.

The device is engineered to deliver retinal therapeutics through a specially designed microcatheter, which is deployed into the posterior region of the suprachoroidal space. The microcatheter is illuminated allowing trans-scleral visualization by direct observation. This provides absolute confirmation of accurate placement of the microcatheter. The microcatheter is also lubricious and flexible to promote advancement and employs an atraumatic (soft) tip to promote safety.

A 27-gauge needle, which accommodates variation in scleral thickness across most patients, is inserted in the pars plana of the eye. As the needle advances, the microcatheter deploys automatically once the tip of the needle reaches the suprachoroidal space. The microcatheter advances posteriorly toward the macula, the precise location where the drug product will be delivered.

Once accurate placement of the illuminated microcatheter along the posterior retina and macula is confirmed by the physician, the drug product can be accurately and safely delivered.  The drug product is deposited at the deployment site and the natural physiological flows of the suprachoroidal space move the drug product back toward the macula.

Oxulumis

Key benefits of suprachoroidal space delivery

  • Less invasive than intravitreal delivery
  • Reduces side effects
  • Acts as a depot for sustained release drug formulations

Key benefits of Oxulumis

  • Pars plana administration site
  • Visual confirmation of drug placement
  • Delivery of drug alongside the posterior retina and macula
  • Minimally invasive procedure does not penetrate ocular cavity
  • Microcatheter is atraumatic
  • Novel, in-office procedure offers high-value professional fee for physicians
Scroll to Top